Related Experiment Video
Updated: Mar 21, 2026

Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy
Koichi Honda1, Masataka Seike1, Junya Oribe1
1Koichi Honda, Masataka Seike, Junya Oribe, Mizuki Endo, Mie Arakawa, Hiroki Syo, Masao Iwao, Masanori Tokoro, Junko Nishimura, Tetsu Mori, Kazunari Murakami, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu-City, Oita 879-5593, Japan.
Aim:
To identify factors that influence long-term liver function following radiofrequency ablation (RFA) in patients with viral hepatitis-related hepatocellular carcinoma.
Methods:
A total of 123 patients with hepatitis B virus- or hepatitis C virus-related hepatocellular car-cinoma (HCC) (n = 12 and n = 111, respectively) were enrolled. Cumulative rates of worsening Child-Pugh (CP) scores (defined as a 2-point increase) were examined.
Results:
CP score worsening was confirmed in 22 patients over a mean follow-up period of 43.8 ± 26.3 mo. Multivariate analysis identified CP class, platelet count, and aspartate aminotransferase levels as signi-ficant predictors of a worsening CP score (P = 0.000, P = 0.011 and P = 0.024, respectively). In contrast, repeated RFA was not identified as a risk factor for liver function deterioration.
Conclusion:
Long-term liver function following RFA was dependent on liver functional reserve, the degree of fibrosis present, and the activity of the hepatitis condition for this cohort. Therefore, in order to maintain liver function for an extended period following RFA, suppression of viral hepatitis activity is important even after the treatment of HCC.
More Related Videos
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
Related Concept Videos
Drug Toxicity: Risk factors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test